logo

Agios Pharmaceuticals, Inc. (AGIO)



Trade AGIO now with
  Date
  Headline
9/10/2019 7:05:23 AM Agios To Present Phase 3 ClarIDHy Study Data Of TIBSOV At ESMO
2/25/2019 7:20:06 AM Agios Pharma Presents Updated Data From Phase 1 Study Of Ivosidenib In Combination With Azacitidine
2/20/2019 7:05:15 AM Agios Announces FDA Acceptance Of SNDA For TIBSOVO
11/16/2018 7:07:03 AM Agios Pharma Presents Updated Data From Ongoing Phase 1 Study Of Single Agent AG-881 In Advanced Glioma
8/17/2018 4:10:51 AM New Drugs Approved In July
8/2/2018 7:21:05 AM Agios Q2 Net Loss $68.7 Mln Vs Loss Of $83.1 Mln Last Year
3/19/2018 7:08:24 AM Agios Pharma Announces Dosing Of First Patient In A Phase 1 Study Of AG-270
2/14/2018 7:09:43 AM Agios Pharma Posts Q4 Net Loss Of $88.28 Mln Or $1.81/share
1/18/2018 9:01:50 PM Agios Announces Pricing Of $475 Mln Public Offering Of Common Stock
1/17/2018 4:05:14 PM Agios Announces Proposed Offering Of Common Stock
6/13/2016 9:34:48 AM Canaccord Ups Agios Pharmaceuticals, Inc. (AGIO) To Buy From Hold With $90 Up From $50 Price Target
3/4/2016 10:22:52 AM Canaccord Is Lowering Agios Pharmaceuticals, Inc. (AGIO) 2016 Rev. Estimate To 84 M From 119 M